Archive for January, 2009

Business Wire - King Pharmaceuticals Reports DREAM Data on Ramipril; Results Presented at the European Association for the Study Of Diabetes and Published in the New England…

Thursday, January 8th, 2009

BRISTOL, Tenn. — King Pharmaceuticals, Inc. (NYSE:KG) today reported that the results of the Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication study (”DREAM”) were presented at the European Association for the Study of Diabetes (”EASD”) meeting in Copenhagen, Denmark, …

Internal Medicine News - Ramipril cuts diabetes risk

Saturday, January 3rd, 2009

The ACE inhibitor ramipril appears to reduce the risk of developing diabetes among high-risk patients who take it to prevent myocardial infarction, stroke, and diabetic nephropathy, reported Salim Yusuf, D.Phil., and associates in the Heart Outcomes Prevention Evaluation trial.
The HOPE trial involved more than 10,000 subjects treated at 267 hospitals around the world between 1994 and 1999. A subgroup of 5,887 patients who were at risk for diabetes but did n…